Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 46

Related Articles by Review for PubMed (Select 19666212)

1.

A potential role for crystallization inhibitors in treatment of Alzheimer's disease.

Grases F, Costa-Bauzà A, Prieto RM.

Med Hypotheses. 2010 Jan;74(1):118-9. doi: 10.1016/j.mehy.2009.07.029. Epub 2009 Aug 8.

PMID:
19666212
2.

An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: implications for Alzheimer's disease.

Pappolla MA, Chyan YJ, Poeggeler B, Frangione B, Wilson G, Ghiso J, Reiter RJ.

J Neural Transm. 2000;107(2):203-31. Review.

PMID:
10847561
3.

Role of melatonin in Alzheimer-like neurodegeneration.

Wang JZ, Wang ZF.

Acta Pharmacol Sin. 2006 Jan;27(1):41-9. Review.

4.

Non-cholinergic strategies for treating and preventing Alzheimer's disease.

Doraiswamy PM.

CNS Drugs. 2002;16(12):811-24. Review.

PMID:
12421115
5.

Amyloid beta-protein toxicity and oxidative stress in Alzheimer's disease.

Behl C.

Cell Tissue Res. 1997 Dec;290(3):471-80. Review.

PMID:
9369525
6.

The human pineal gland and melatonin in aging and Alzheimer's disease.

Wu YH, Swaab DF.

J Pineal Res. 2005 Apr;38(3):145-52. Review.

PMID:
15725334
7.

Role of melatonin in neurodegenerative diseases.

Srinivasan V, Pandi-Perumal SR, Maestroni GJ, Esquifino AI, Hardeland R, Cardinali DP.

Neurotox Res. 2005;7(4):293-318. Review.

PMID:
16179266
8.

Beneficial effects of melatonin in experimental models of Alzheimer disease.

Cheng Y, Feng Z, Zhang QZ, Zhang JT.

Acta Pharmacol Sin. 2006 Feb;27(2):129-39. Review.

9.
10.

Development of indole-3-propionic acid (OXIGON) for Alzheimer's disease.

Bendheim PE, Poeggeler B, Neria E, Ziv V, Pappolla MA, Chain DG.

J Mol Neurosci. 2002 Aug-Oct;19(1-2):213-7. Review.

PMID:
12212784
11.

Antioxidants and neuroprotection in the adult and developing central nervous system.

Kaur C, Ling EA.

Curr Med Chem. 2008;15(29):3068-80. Review.

PMID:
19075654
12.

Melatonin: new places in therapy.

Maharaj DS, Glass BD, Daya S.

Biosci Rep. 2007 Dec;27(6):299-320. Review.

13.

Immunological approaches for amyloid-beta clearance toward treatment for Alzheimer's disease.

Solomon B.

Rejuvenation Res. 2008 Apr;11(2):349-57. doi: 10.1089/rej.2008.0689. Review.

PMID:
18341423
14.

Melatonin oxidative stress and neurodegenerative diseases.

Srinivasan V.

Indian J Exp Biol. 2002 Jun;40(6):668-79. Review.

PMID:
12587715
15.

Therapeutic potential of oxidant mechanisms in Alzheimer's disease.

Moreira PI, Smith MA, Zhu X, Santos MS, Oliveira CR, Perry G.

Expert Rev Neurother. 2004 Nov;4(6):995-1004. Review.

PMID:
15853526
16.

Developing injectable immunoglobulins to treat cognitive impairment in Alzheimer's disease.

Steinitz M.

Expert Opin Biol Ther. 2008 May;8(5):633-42. doi: 10.1517/14712598.8.5.633 . Review.

PMID:
18407766
17.

Amyloid, cholinesterase, melatonin, and metals and their roles in aging and neurodegenerative diseases.

Lahiri DK, Chen DM, Lahiri P, Bondy S, Greig NH.

Ann N Y Acad Sci. 2005 Nov;1056:430-49. Review.

PMID:
16387707
18.

Nutritional antioxidants and the heme oxygenase pathway of stress tolerance: novel targets for neuroprotection in Alzheimer's disease.

Calabrese V, Butterfield DA, Stella AM.

Ital J Biochem. 2003 Dec;52(4):177-81. Review.

PMID:
15141484
19.

Neuroprotective approaches in experimental models of beta-amyloid neurotoxicity: relevance to Alzheimer's disease.

Harkany T, Hortobágyi T, Sasvári M, Kónya C, Penke B, Luiten PG, Nyakas C.

Prog Neuropsychopharmacol Biol Psychiatry. 1999 Aug;23(6):963-1008. Review.

PMID:
10621945
20.

The role of oxidative stress in the toxicity induced by amyloid beta-peptide in Alzheimer's disease.

Miranda S, Opazo C, Larrondo LF, Muñoz FJ, Ruiz F, Leighton F, Inestrosa NC.

Prog Neurobiol. 2000 Dec;62(6):633-48. Review.

PMID:
10880853
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk